The Food and Drug Administration (FDA) says it needs more information about dosing and side effects for a new antipsychotic medication before it will decide whether to approve the drug. The drug candidate cariprazine, made by Forest Laboratories Inc., is designed to treat Bipolar I disorder, a type of manic-depressive illness characterized by unusual shifts in a person’s mood that can interfere with daily activities. It is also designed to treat schizophrenia, a conditions with symptoms such as hallucinations, delusions and social withdrawal. The drug is also being tested, though approval not yet sought, as a potential adjunct in treatment-resistant ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.